---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-288474"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2023-12-04T23:59:59+00:00"
generated_at: "2026-06-07T18:43:10.477449+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# NeuroPace enters $3.7M collaboration with Rapport for Phase 2a trial of RAP compound

## Summary
- Agreement with Rapport Therapeutics to support Phase 2a trial of GAMA 8 Receptor-Associated Protein (RAP) compound.
- NeuroPace provides site data and monitoring capabilities for RNS System patients enrolled in the trial.
- Agreement spans nine quarters (Q4 2023 to Q4 2025) with milestones, subject to early termination provisions.
- Total anticipated revenue from collaboration is approximately $3.7 million, including a trial initiation payment in Q4 2023.

## SEC filing metadata
- accession: 0001193125-23-288474
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2023-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000119312523288474/0001193125-23-288474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000119312523288474/d601207d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-288474
- JSON: https://secwatch.observer/filing/0001193125-23-288474.json
- Plain text: https://secwatch.observer/filing/0001193125-23-288474.txt

## Key facts
- Material Agreements
  NeuroPace Inc entered into Agreement with Rapport Therapeutics, Inc. valued at approximately $3.7 million (effective 2023-11-28).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Rapport Therapeutics, Inc.
  - Value: approximately $3.7 million
  - Effective: 2023-11-28
  source text: On November 28, 2023 NeuroPace, Inc. entered into a collaboration agreement (“Agreement”) with Rapport Therapeutics, Inc. (“Rapport”), pursuant to which NeuroPace will provide certain site data for Rapport to use in targeting potential patients for their Phase 2a trial of their GAMA 8 Receptor-Associated Protein (“RAP”) compound
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000119312523288474/0001193125-23-288474-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.